Β-Thalassemia Treatment with KL003 Cell Injection

Summary

This is a non-randomized, open label, single-dose study in up to 41 participants with β-thalassemia major. The goal of this clinical trial is to evaluate the safety and efficacy of KL003 cell injection in subjects with β-thalassemia major.

Timeline

Start

2024-04-05

Primary completion

2025-10

Completion

2027-05

Drugs

Indications